Presentation Title
My name
My position, contact information
or project description
Digene
About the company
Founded in 1888, by a young Chicago based physician, Dr. Wallace Calvin Abbott,
the organization has been devoted to discovering new medicines,
new technologies and new ways to manage health
Abbott India Limited is one of India's fastest growing pharmaceutical companies
and part of Abbott's Global Pharmaceutical business in India
Executive Summary
Results 2014
2014 Key insights
In Rs Cr. 2014 2015
Sales Target 100 123
Market Share 17% 19%
 Successful re-launch of brand Digene in 2014
▪ Brand achieves growth after stagnation of 4 years
▪ Brand franchise successfully extended through
entry into high growth category of Powders
▪ Category of Antacids poised to reach Rs.2000 Crores
by 2020
▪ Low penetration of the category poses high potential
for growth
▪ Prescriptions for Antacids are declining as they lose
preference to PPIs
▪ Growths of Gels and Tablets are flattening
Brand Plan devised based on research
various
researches
various
cities
various
respondents
depth
interviews
HCPs +
Chemists
Fizz launch
Digene Fizz Launch (activities till date)
Sales
▪On course to achieve huge monthly sachet
sales by Dec’15
Media
▪High frequency announcer film
▪Aired across all major GEC, News and
Movie Channels
▪Extensive reach
BTL
▪Extensive Visibility across the country
– numerous posters & dangler
dispenser
▪Sampling
– sachets sampled to retailers and
wholesalers
Digene is the number 2 player in overall antacids
Category evolution continues
towards Powders
Reach in chemists similar across segments.
65% of powder sales occur outside of chemists
Gel & Tabs growths are stagnating
Powders has evolved to be the biggest segment
Market Share
▪ Eno continues to dominate the
Powders’ category with >92% market
share
▪ Digene Fizz is at ever highest share
(higher than Fastmelt)
▪ Digene Gels – Overtaken Gelusil in
Q3’14
Tablets Market Share Gels Market Share
Digene Powder Market Share
Brand Re-launched with multiple improvements
Superior Taste Profile
▪ Existing flavours’ taste profile
enhanced with cooling
New Communication
▪ New Thematic commercial
▪ Tactical announcer film for Fizz
Rural Outreach
▪ Increased distribution to smaller towns
Revamped Packaging
▪ Consumer-friendly, less-
medicinal look
▪ Replaced glass bottle
with PET
Sales team expansion
▪ Expansion of sales force to cater to the
OTC market
Product
Consumerization of Brand
 Reposition the brand to create
emotional connect and
strengthen functional connect
with the consumers
 Existing flavours’ taste profile
enhanced with cooling
Price
Place
Promotion
Segmentation and Targeting
India’s population 1360m1360m 1400m1400m
Rs. 2,000CrRs. 2,000Cr
2015 2020
Population suffering
from acidity 870m870m
Population taking
remedy 830m830m
Total modern remedy
users 329m329m
1015m1015m
960m960m
453m453m
Assumptions
Decadal population
growth rate of 17.6%
Increase in urbanization
from 33.5% in 2015 to
36% in 2020
Increased accessibility &
acceptability to drive
growth by ~5%
Total Estimated Market
Segmentation and Targeting
Consumer driven Medicinal
“Serious” suffering“Casual” suffering
Target all sufferers of acidity and not only
current users of modern remedies
Points of Difference

Bm_Kashvi Jain_sec b

  • 1.
    Presentation Title My name Myposition, contact information or project description Digene
  • 2.
    About the company Foundedin 1888, by a young Chicago based physician, Dr. Wallace Calvin Abbott, the organization has been devoted to discovering new medicines, new technologies and new ways to manage health Abbott India Limited is one of India's fastest growing pharmaceutical companies and part of Abbott's Global Pharmaceutical business in India
  • 3.
    Executive Summary Results 2014 2014Key insights In Rs Cr. 2014 2015 Sales Target 100 123 Market Share 17% 19%  Successful re-launch of brand Digene in 2014 ▪ Brand achieves growth after stagnation of 4 years ▪ Brand franchise successfully extended through entry into high growth category of Powders ▪ Category of Antacids poised to reach Rs.2000 Crores by 2020 ▪ Low penetration of the category poses high potential for growth ▪ Prescriptions for Antacids are declining as they lose preference to PPIs ▪ Growths of Gels and Tablets are flattening
  • 4.
    Brand Plan devisedbased on research various researches various cities various respondents depth interviews HCPs + Chemists
  • 5.
    Fizz launch Digene FizzLaunch (activities till date) Sales ▪On course to achieve huge monthly sachet sales by Dec’15 Media ▪High frequency announcer film ▪Aired across all major GEC, News and Movie Channels ▪Extensive reach BTL ▪Extensive Visibility across the country – numerous posters & dangler dispenser ▪Sampling – sachets sampled to retailers and wholesalers
  • 6.
    Digene is thenumber 2 player in overall antacids Category evolution continues towards Powders Reach in chemists similar across segments. 65% of powder sales occur outside of chemists Gel & Tabs growths are stagnating Powders has evolved to be the biggest segment
  • 7.
    Market Share ▪ Enocontinues to dominate the Powders’ category with >92% market share ▪ Digene Fizz is at ever highest share (higher than Fastmelt) ▪ Digene Gels – Overtaken Gelusil in Q3’14 Tablets Market Share Gels Market Share Digene Powder Market Share
  • 8.
    Brand Re-launched withmultiple improvements Superior Taste Profile ▪ Existing flavours’ taste profile enhanced with cooling New Communication ▪ New Thematic commercial ▪ Tactical announcer film for Fizz Rural Outreach ▪ Increased distribution to smaller towns Revamped Packaging ▪ Consumer-friendly, less- medicinal look ▪ Replaced glass bottle with PET Sales team expansion ▪ Expansion of sales force to cater to the OTC market
  • 9.
    Product Consumerization of Brand Reposition the brand to create emotional connect and strengthen functional connect with the consumers  Existing flavours’ taste profile enhanced with cooling
  • 10.
  • 11.
  • 12.
  • 13.
    Segmentation and Targeting India’spopulation 1360m1360m 1400m1400m Rs. 2,000CrRs. 2,000Cr 2015 2020 Population suffering from acidity 870m870m Population taking remedy 830m830m Total modern remedy users 329m329m 1015m1015m 960m960m 453m453m Assumptions Decadal population growth rate of 17.6% Increase in urbanization from 33.5% in 2015 to 36% in 2020 Increased accessibility & acceptability to drive growth by ~5% Total Estimated Market
  • 14.
    Segmentation and Targeting Consumerdriven Medicinal “Serious” suffering“Casual” suffering Target all sufferers of acidity and not only current users of modern remedies
  • 15.